Related Experiment Videos
Experimental immunoglobulin A nephropathy induced by gram-negative bacteria
1Department of Immunology, Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
Nephron
|January 1, 1993
Summary
Researchers developed a new model for IgA nephropathy using gram-negative bacteria in mice. This study shows bacterial cell wall components, not just LPS, are key to IgA and C3 deposition in the kidneys.
Area of Science:
- Immunology
- Nephrology
- Microbiology
Background:
- Immunoglobulin A (IgA) nephropathy is a kidney disease.
- The role of gram-negative bacteria in IgA nephropathy pathogenesis is not fully understood.
- Lipopolysaccharide (LPS) is a known component of gram-negative bacteria.
Purpose of the Study:
- To investigate if formalin-fixed gram-negative bacteria induce glomerular deposition of IgA and C3 in mice.
- To determine if bacterial cell wall components other than LPS contribute to IgA nephropathy.
- To establish an active mouse model for IgA nephropathy.
Main Methods:
- Mice were administered formalin-fixed strains of Pseudomonas aeruginosa, Escherichia coli, Haemophilus influenzae, and Klebsiella pneumoniae intraperitoneally.
- Lipopolysaccharide (LPS) and bacterial fractions were also administered.
- Sequential glomerular changes were examined, and serum IgA, IgG, and IgM levels were quantified using ELISA.
Main Results:
- Intraperitoneal administration of whole bacterial cells significantly increased glomerular IgA and C3 deposition compared to LPS or control groups.
- The incidence of immunofluorescence positivity for glomerular IgA and C3 ranged from 37-71% and 37-66.7%, respectively.
- These findings indicate a role for bacterial cell wall components beyond LPS.
Conclusions:
- Cell wall components common to gram-negative bacteria, excluding LPS, are crucial for glomerular IgA and C3 deposition.
- This study presents the first active mouse model of IgA nephropathy induced by gram-negative bacteria.
- Further research into these bacterial components may reveal new therapeutic targets for IgA nephropathy.